Search Results
Your search for ,Non matches 5540 pages
Showing 2351 - 2400Rates of Testicular Cancer Rising Among Racial/Ethnic Minorities in the United States
Between 2001 and 2016 in the United States, Asian/Pacific Islander men experienced the greatest increase in the incidence of testicular germ cell tumors, followed by Hispanic and American Indian/Alaska Native men, according to a study published by Ghazarian et al in Cancer Epidemiology, Biomarkers...
Safety and Patient-Reported Outcomes From the IMpower150 Trial in Metastatic Nonsquamous NSCLC
A safety and patient-reported outcome analysis from the IMpower150 trial, reported in the Journal of Clinical Oncology by Martin Reck, PhD, and colleagues, indicated that atezolizumab plus bevacizumab and chemotherapy appeared to be a manageable and tolerable regimen when compared with atezolizumab ...
Sacituzumab Govitecan-hziy for Previously Treated Metastatic Triple-Negative Breast Cancer
On April 22, 2020, the antibody-drug conjugate sacituzumab govitecan-hziy was granted accelerated approval for treatment of adult patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease.1,2 Supporting Efficacy Data Approval was...
Men of Color Remain Underrepresented in Prostate Cancer Clinical Trials
An analysis of 59 prostate cancer clinical trials based in North America and Europe found that the vast majority of enrollees were non-Hispanic white men, according to a study published by Rencsok et al in Cancer Epidemiology, Biomarkers & Prevention. The proportion of white participants in...
RET Kinase Inhibitor for Patients With Solid Tumors and RET Genetic Fusions
The RET inhibitor pralsetinib showed activity in patients with a broad variety of tumors harboring RET gene fusions, according to results from the phase I/II ARROW trial, presented by Vivek Subbiah, MD, and colleagues during the ASCO20 Virtual Scientific Program (Abstract 109). “This trial shows...
Study Finds Substantial Racial/Ethnic Disparities in Lost Earnings From Cancer Mortality
Disparities in cancer mortality rates between black and white Americans date back more than 60 years. Now, a study by the American Cancer Society comparing person-years of life lost and lost earnings due to premature cancer mortality by race/ethnicity has quantified the economic burden due to...
A Lung Cancer Specialist’s Winding Journey From Venezuela to Wisconsin
Lung cancer specialist Narjust Duma, MD, was born and reared in Mérida, Venezuela, a city nestled on a plateau in the Venezuelan Andes. “I’m the daughter of two surgeons. After my parents divorced, I lived with my mother and spent a lot of time at the hospital where she worked. When she was in...
Cediranib/Olaparib vs Standard-of-Care Chemotherapy for Platinum-Sensitive Ovarian Cancer
Results of the NRG Oncology phase III clinical trial NRG-GY004 indicated that the addition of the investigational agent cediranib to olaparib and standard platinum-based chemotherapy did not improve progression-free survival outcomes for women with platinum-sensitive ovarian cancer; however,...
Internationally Regarded Cancer Immunologist Did Not Stray Far From Home
Internationally recognized immune-oncology melanoma expert Jedd D. Wolchok, MD, PhD, FASCO, was born and reared in Staten Island, not far from where he would shape his noted career at Memorial Sloan Kettering Cancer Center (MSK) in New York, New York. “I went to Princeton University and, during my ...
Love of Science, Passion for Research, and Belief in the Power of the Immune System
Steven A. Rosenberg, MD, PhD, FASCO, knew from the start of his medical career that if treatments for cancer were to become curative, research in new therapies would have to move away from the mainstay one-size-fits-all approach of systemic chemotherapy to an innovative, personalized strategy that ...
Tepotinib Shows Activity in Patients With NSCLC and MET Exon 14–Skipping Mutation
Patients with advanced non–small cell lung cancer (NSCLC) and a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping had a 46.5% objective response rate to the targeted therapy drug tepotinib, as shown in a study presented during the ASCO20 Virtual Scientific Program...
Is Sentinel Lymph Node Biopsy Alone Oncologically Safe for Patients With Early-Stage Cervical Cancer?
In a study of patients with early-stage cervical cancer presented by Balaya et al during the Gynecologic Cancer Oral Abstract Session of the ASCO20 Virtual Scientific Program (Abstract 6006), researchers assessed disease-free and disease-specific survival to determine whether sentinel lymph node...
FDA Approves First-Line Ramucirumab Plus Erlotinib for Metastatic EGFR-Mutated NSCLC
On May 29, the U.S. Food and Drug Administration (FDA) approved ramucirumab (Cyramza, injection, 10 mg/mL solution) in combination with erlotinib for the first-line treatment of patients with metastatic non–small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19...
Study Finds Patients With Lung Cancer Infected With COVID-19 Are at High Risk for Hospitalization
Data from the global TERAVOLT Consortium, which is investigating the impact of COVID-19 infection on patients with thoracic cancers, have found that these patients are at high risk for hospitalization and death. Prior use of chemotherapy was associated with an increased risk of mortality, as was...
Adjuvant Osimertinib in Early-Stage EGFR-Positive NSCLC
Adjuvant osimertinib significantly improved disease-free survival compared with placebo in patients with stage IB to IIIA EGFR-mutated non–small cell lung cancer (NSCLC) who underwent complete resection of primary tumor and received chemotherapy if indicated. These results from the first interim...
Lymphoma: Many Questions, Too Few Answers
The successful treatment of malignant lymphoma has been one of the great achievements in medical oncology, but certainly more work is needed to define key biologic targets as well as molecular markers for a more accurate definition of prognosis following therapy. In day-to-day practice, unanswered...
Roy S. Herbst, MD, PhD, on NSCLC: Osimertinib in Stage IB–IIIA EGFR Mutation–Positive Disease
Roy S. Herbst, MD, PhD, of Yale Cancer Center, discusses data from the ADAURA study, which showed that compared with placebo, osimertinib as adjuvant therapy after complete tumor resection reduced the risk of disease recurrence or death by 79% in patients with non–small cell lung cancer (Abstract...
FDA Approves Brigatinib for ALK-Positive Metastatic NSCLC
On May 22, the U.S. Food and Drug Administration (FDA) approved brigatinib (Alunbrig) for adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non–small cell lung cancer (NSCLC) as detected by an FDA-approved test. The FDA also approved the Vysis ALK Break Apart FISH Probe Kit...
The Arc of Therapy—From Cure to Humbling Legacy
The ASCO Post is pleased to reproduce installments of Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays, historical...
Sleeping Well After Cancer: Patient-Centered Research for Treatment of Insomnia
Insomnia is a persistent sleep disorder that affects nearly 60% of people with cancer, diminishing their quality of life.1,2 Chronic insomnia disorder is defined by trouble falling asleep, staying asleep, or waking too early three times per week for 3 months or more.3 Standard care comprises...
Overcoming the Challenges of Presenting the ASCO Annual Meeting During the COVID-19 Pandemic
As the worldwide cases of the coronavirus started to mount in February and March, medical societies and organizations monitoring the escalating COVID-19 pandemic and its impact on international and domestic travel made the difficult decision to postpone or cancel their scientific conferences. On...
United Against Cancer to Accelerate Progress for Patients
When I chose my Presidential theme for the 2020 ASCO Annual Meeting, “Unite and Conquer: Accelerating Progress Together,” in early 2019, I never imagined it would take on a new meaning 12 months later. The world is grappling with the COVID-19 pandemic, and, even as we practice social distancing, I...
Opioid-Related Deaths in the Cancer Population vs the General Population
In a study reported in a research letter in JAMA Oncology, Fumiko Chino, MD, and colleagues found that while the incidence of opioid-related death has increased in both the general population and in patients with cancer in recent years, opioid-related death is far less common among individuals with ...
Neoadjuvant Atezolizumab Plus Chemotherapy for Resectable NSCLC
In a phase II study reported in The Lancet Oncology, Shu et al found that neoadjuvant treatment with atezolizumab plus nab-paclitaxel/carboplatin produced a major pathologic response in 57% of patients and a complete pathologic response in 33% of patients with resectable, predominantly stage IIIA...
ASCO Special Report Provides Guidance to Oncology Practices on Resuming Cancer Care During the COVID-19 Pandemic
ASCO has released the ASCO Special Report: A Guide to Cancer Care Delivery During the COVID-19 Pandemic, which provides detailed guidance to oncology practices on the immediate and short-term steps that could be taken to help protect the safety of patients and health-care staff before resuming more ...
Low-Intensity Surveillance as an Option for Some Patients With Non–Muscle Invasive Bladder Cancer
Low-intensity cystoscopic surveillance may be a viable option for patients with high-risk, non–muscle invasive bladder cancer, according to data from a paper presented to the media during a special session moderated by the American Urological Association (AUA) on May 15. The research was also...
NIH-Led ACTIV Program for the Development of COVID-19 Vaccines
In an article published in Science, Lawrence Corey, MD; John R. Mascola, MD; Anthony S. Fauci, MD; and Francis S. Collins, MD, PhD, describe the composition and aims of the National Institutes of Health (NIH)-led Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership....
FDA Approves Atezolizumab for the First-Line Treatment of Patients With Metastatic NSCLC and High PD-L1 Expression
On May 18, the U.S. Food and Drug Administration (FDA) approved atezolizumab (Tecentriq) for the first-line treatment of adult patients with metastatic non–small cell lung cancer (NSCLC) whose tumors have high programmed cell death ligand 1 (PD-L1) expression (PD-L1 stained ≥ 50% of tumor cells or...
Qi Liu, PhD, on NSCLC: Pneumonitis, Immunotherapy, and Chemotherapy
Qi Liu, PhD, of the U.S. Food and Drug Administration, discusses data that suggest that patients with advanced non–small cell lung cancer who had a past medical history of pneumonitis were more likely to experience treatment-associated pneumonitis in response to immune checkpoint inhibitors or...
Physical Activity and Neurocognitive Function in Adult Survivors of Childhood Cancers
In a Childhood Cancer Survivor Study analysis reported in the Journal of Clinical Oncology, Barlow-Krelina et al found that consistent physical activity vs consistent inactivity was associated with reduced neurocognitive problems and greater improvement in neurocognitive domains during long-term...
FDA Pipeline: Two Breakthrough Therapy Designations for Fam-Trastuzumab Deruxtecan-nxki, and More
Over the past few weeks, the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designations for an antibody-drug conjugate in the treatment of gastric and lung cancers. The Agency has also issued Orphan Drug designations for agents being investigated in chronic myeloid...
FDA Approves Nivolumab/Ipilimumab for First-Line Treatment of Patients With Metastatic NSCLC and PD-L1 Tumor Expression ≥ 1%
On May 15, 2020, the U.S. Food and Drug Administration (FDA) approved the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) as first-line treatment for patients with metastatic non–small cell lung cancer (NSCLC) whose tumors express programmed cell death ligand 1 (PD-L1) at ≥ 1%, as...
Selected Poster Presentations on Cancer Therapeutics and More
Although the live 2020 National Comprehensive Cancer Network (NCCN) Annual Conference was canceled, more than 100 posters scheduled for presentation are now available online, as part of the NCCN 2020 Virtual Annual Conference. The ASCO Post has summarized some of the clinical trial updates we found ...
Combining Pembrolizumab With IL-12 Electroporation May Improve Clinical Response in Patients With Immunologically 'Cold' Melanoma
Patients with non–immune-infiltrated “cold” tumors have low frequencies of intratumoral tumor-reactive, checkpoint-positive cytotoxic lymphocytes, making them less responsive to checkpoint blockage than patients with immune-infiltrated “hot” tumors. A phase II study by Alain P. Algazi, MD, and...
Edward B. Garon, MD, on Metastatic NSCLC: GEOMETRY mono-1 Trial of Capmatinib
Edward B. Garon, MD, of the University of California, Los Angeles, David Geffen School of Medicine, discusses results from a small study in METex14-mutated advanced non–small cell lung cancer and brain metastases. The trial suggested capmatinib showed antitumor activity in the brain, regardless of...
Edward B. Garon, MD, on NSCLC: Long-Term Use of Pemetrexed Plus Platinum With Pembrolizumab
Edward B. Garon, MD, of the University of California, Los Angeles David Geffen School of Medicine, discusses KEYNOTE-189 trial findings that showed adding pembrolizumab to pemetrexed plus platinum—which previously was found to improve overall and progression-free survival—is also safe and has...
Byoung Chul Cho, MD, PhD, on NSCLC: Genetic Mutations and Immunotherapy vs Chemotherapy in KEYNOTE-042
Byoung Chul Cho, MD, PhD, of Yonsei Cancer Center and Severance Hospital, discusses the STK11 and KEAP1 mutations in non–small cell lung cancers, and their relationship to the efficacy of pembrolizumab monotherapy vs platinum-based chemotherapy as first-line treatment for PD-L1–positive advanced...
AACR 2020: Continuous Dosing of Dabrafenib Plus Trametinib Improves Progression-Free Survival vs Intermittent Dosing in Advanced Melanoma
Continuous dosing with dabrafenib and trametinib improved progression-free survival in patients with BRAF-mutated advanced melanoma compared with an intermittent-dosing strategy, according to results of the phase II SWOG S1320 randomized trial reported at the opening Plenary Session of the 2020...
Ruxolitinib in Glucocorticoid-Refractory Acute Graft-vs-Host Disease After Stem Cell Transplant
In the phase III REACH2 trial reported in The New England Journal of Medicine, Zeiser et al found that the JAK1/2 inhibitor ruxolitinib improved response rate vs investigator’s choice of therapy in patients with glucocorticoid-refractory acute graft-vs-host disease (GVHD) following allogeneic stem...
Can a Culturally Tailored Education Program Improve Colorectal Cancer Awareness and Screening?
People who received information from the Screen to Save program, a culturally tailored initiative from the National Cancer Institute (NCI) Center to Reduce Cancer Health Disparities (CRCHD), increased their knowledge of colorectal cancer and indicated willingness to adopt potentially preventive...
FDA Approves Selpercatinib for Lung and Thyroid Cancers With RET Mutations or Fusions
On May 8, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to selpercatinib (Retevmo) for the following indications: Adult patients with metastatic RET fusion–positive non–small cell lung cancer (NSCLC) Adult and pediatric patients ≥ 12 years of age with advanced or...
Highlights From ASH 2019 Included New Data in Leukemia, Lymphoma, Myeloma, and Myelodysplastic Syndromes
The 2019 American Society of Hematology (ASH) Annual Meeting & Exposition featured a cornucopia of sessions. It was impossible to attend all the lectures, symposia, oral presentations, poster presentations, and special events because many were concurrent. Below, we have selected some...
Bispecific Antibodies Poised to Impact Treatment of Lymphoma and Other Blood Cancers
Studies of second-generation bispecific antibodies were among the highlights of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition. The bispecific T-cell engager blinatumomab was the first such agent to be approved by the U.S. Food and Drug Administration (FDA) in...
Addition of Pembrolizumab to Docetaxel for Previously Treated Immunotherapy-Naive Patients With Advanced Lung Cancer
In the single-institution phase II PROLUNG trial reported in JAMA Oncology, Oscar Arrieta, MD, and Christian Rolfo, MD, PhD, and colleagues found that the addition of pembrolizumab to docetaxel improved objective response rates and progression-free survival in immunotherapy-naive patients with...
Can Breast Cancer Surgery Be Eliminated in ‘Exceptional Responders’ to Neoadjuvant Therapy?
Can patients with breast cancer who achieve an “exceptional response” to neoadjuvant therapy safely forgo surgery? That is a question being seriously explored in multinational trials. “We’ve known for a long time that we can eliminate disease in many patients if they have chemosensitive tumors....
Early Signs of Activity With Immunotherapies in Low-Incidence Cancers
Immunotherapy is showing promise for patients with rare cancers, offering new treatment opportunities and clinical trials to those with previously limited options. At the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium, presenters discussed the use of immunotherapy in three low-incidence cancers: ...
Novel Treatment Strategies Under Study in Advanced Melanoma
Several novel strategies for the treatment of patients with stage III or IV melanoma showed promise in studies presented at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium.1,2 Vaccine for High-Risk Patients After Resection A tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine was...
PARP Inhibitors in Maintenance Treatment for Advanced Ovarian Cancer
Based on multiple phase III prospective trials, there is evidence that both PARP inhibitors and antiangiogenic therapies such as bevacizumab provide benefit when utilized in a maintenance strategy in the first-line treatment of advanced epithelial ovarian cancer (GOG 218, ICON7, SOLO-1, PRIMA,...
Reduction in Cancer Diagnoses in the Netherlands During the COVID-19 Pandemic
In a commentary published in The Lancet Oncology, Dinmohamed et al detailed a nationwide reduction in cancer diagnoses in the Netherlands in the several weeks following the first confirmed case of COVID-19 in the country compared with the several weeks preceding the first documented case. This...
Mehdi Hamadani, MD: In My Experience Question 5
For community oncologists treating patients with non-Hodgkin lymphoma during the COVID-19 pandemic, what resources and clinical pearls would you suggest? Recorded April 21, 2020.
